"We [began] the year with the acquisition [by Huntsworth], which is going well," says president Nancy Bacher Long. "We now have our bona fide global footprint."
Turnover was about 20%. Headcount held at 45. Founders Rita and Harry Sweeney left in December. EVP Marylou McNally also left. Senior management was restructured and a new executive committee was named. Senior hires include Michael Beckerich, EVP, and Peter Collins, SVP, director of media relations.
A new-media practice was formalized. VP Meghan Hindman will direct it. Maryellen Royle was promoted to EVP.
A New York office opened in early 2007. Being part of Huntsworth, there is also an office in Boston and two in London. The firm also accesses 70-plus Huntsworth PLC-owned offices worldwide.
Pharma and biotech client portfolios expanded in Philadelphia and San Francisco. Client inroads are being cultivated with sister firms in Europe.
Key account wins include Affymax, NeoVista, and the Association for the Advancement of Cancer Research. Cephalon's Provigil account was lost.
About 80% of business is on yearly contract, with the rest project-based. Many clients have begun new-media efforts.
Revenue is less than $50 million. Dorland reports revenue is on pace with targets, driven largely by continued growth of core client base, as well as new assignments from large pharma, midsize and emerging biopharmaceutical companies, and device and diagnostics businesses.
Principal: Nancy Bacher Long, president, Dorland Global PR; Richard Minoff, CEO and president, Dorland Global
Ownership: Huntsworth Health Co.
Offices: Three in US - Philadelphia (HQ), San Francisco, and New York